Atiye Cenay Karabörk Kılıç

Atiye Cenay Karabörk Kılıç

Auto-generated profile, based on publicly available information

Atiye Cenay Karabörk Kılıç

Department of Radiology Gazi University Faculty of Medicine Ankara Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VAVolkan Aslan
Volkan Aslan
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
AÖAhmet Özet
Ahmet Özet
AÜAytuğ Üner
Aytuğ Üner
NGNazan Günel
Nazan Günel
NÖNuriye Özdemir
Nuriye Özdemir
Introduction: Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immunooncology today is the lack of a predictive factor to identify this patient group. Myeloid-derived suppressor cells (MDSC) are a type of cell that contributes to immunotherapy resistance by inhibiting T cell activity. While it accumulates in the tumor microenvironment and blood, it can also accumulate in lymphoid organs such as the spleen and cause splenomegaly. Therefore we aimed to evaluate the effect of increase in splenic volume, which can be considered as an indirect indicator of increased MDSC cells, on survival outcomes in mRCC patients. Methods: We analyzed 45 patients with mRCC who received nivolumab as a second-line or subsequent therapy. Splenic volume was analyzed from baseline imaging before starting nivolumab and from control imaging performed within the first 6 months of treatment initiation. Additionally, we analyzed how patients’ body mass index (BMI), IMDC risk score, ECOG performance status, nephrectomy status, neutrophil-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and sites of metastasis. Results: Median splenic volume change was 10% (ranging from − 22% to + 117%) during follow-up. Change in splenic volume was found to be associated with overall survival (OS) and progression-free survival (PFS) (p = 0.025, 0.04). The median PFS in patients with increased splenic volume was 5 months, while it was 17 months in patients without increased splenic volume. (HR 2.1, 95% CI (1–4), p = 0.04). The median OS in patients with increased splenic volume was 9 months, while it was 35 months in patients without increased splenic volume (HR 2.7, 95% CI (1.1–6.2), p = 0.025). In four patients with decreased splenic volume, neither PFS nor OS could reach the median value. Log-rank p value in respectively (0.015, 0.035), The group in which an increase in volume was accompanied by a high NLR had the shortest survival rate. Basal splenic volume was analyzed separately. However, neither PFS nor OS differed significantly. Conclusion: Our findings suggest that the change in splenic volume throughout immunotherapy regimens may be utilized to predict PFS and OS in mRCC patients undergoing treatment.

20 September 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
VAVolkan Aslan
Volkan Aslan
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
OSOsman Sutcuoglu
Osman Sutcuoglu
EEEmrah Eraslan
Emrah Eraslan
ABAHMET BAYRAK
AHMET BAYRAK
OYOzan Yazıcı
Ozan Yazıcı

4 March 2024 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KYKadriye Bir Yücel
Kadriye Bir Yücel
UAUguray Aydos
Uguray Aydos
OSOsman Sutcuoglu
Osman Sutcuoglu
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
NÖNuriye Özdemir
Nuriye Özdemir
OYOzan Yazıcı
Ozan Yazıcı

10 September 2022 in Nutrition and Cancer
Verified
Journal Article
Closed access
KYKadriye Bir Yücel
Kadriye Bir Yücel
AKAtiye Cenay Karabork Kilic
Atiye Cenay Karabork Kilic
OSOsman Sutcuoglu
Osman Sutcuoglu
OYOzan Yazıcı
Ozan Yazıcı
UAUguray Aydos
Uguray Aydos
NÖNuriye Özdemir
Nuriye Özdemir
We aimed to evaluate the relationship between sarcopenia, myosteatosis, and systemic inflammatory response biomarkers and their prognostic role in stage 2 and 3 gastric cancer patients.This study i...

28 March 2025 in Hamostaseologie
Verified
Journal Article
Closed access
PDF file
AMAyshan Mammadova
Ayshan Mammadova
KTKübra Taşkaraca
Kübra Taşkaraca
GJGünel Jeyranova
Günel Jeyranova
AOAysel Orujlu
Aysel Orujlu
MTMerve Tatlılıoğlu
Merve Tatlılıoğlu
IOI.Kivilcim Oguzulgen
I.Kivilcim Oguzulgen
High neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of subclinical inflammation and have been associated with prognosis and mortality in many diseases. In this study, we evaluated the comparative value of NLR and PLR in identifying high mortality risk in patients hospitalized with acute pulmonary thromboembolism (PTE), and their relationship with the anatomical burden of thrombus.Patients who were followed up due to PTE were evaluated retrospectively. NLR and PLR were calculated from complete blood counts. The thrombus burden was assessed by the Qanadli score; based on the patients' archival computed tomography angiography images. Mortality prediction was based on an algorithm using the Pulmonary Embolism Severity Index, echocardiographic findings, and troponin levels.Three hundred-two PTE patients were included in the study. Median NLR, PLR, and Qanadli score values were higher in nonsurvivors, with NLR (8.4 [2.2–18.9]) vs. (3.1 [0.4–13.1]), PLR (317 [87.6–525.3]) vs. (124.4 [30–476.3]), and Qanadli scores (21 [3–26]) vs. (9 [1–28]), respectively (p < 0.001). We showed that setting a threshold value of >4.45 for NLR and >151.59 for PLR significantly predicts the high mortality-risk group. In the receiver operating characteristic analysis, when the threshold value for the Qanadli score distinguishing between low-risk and high-risk disease was set at 15.5, the sensitivity was calculated as 98.8% and the specificity was 94.9% (p = 0.001).This study showed that NLR, PLR, and Qanadli scores can provide essential contributions to the clinician's determination of the anatomical burden of thrombus and disease severity in PTE patients.

27 August 2025 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
PDF file
SOSuna Özhan Oktar
Suna Özhan Oktar
MCMahi Nur Cerit
Mahi Nur Cerit
HŞHalit Nahit Şendur
Halit Nahit Şendur
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
Recent advances in vascular ultrasound imaging technology and their clinical implications - Diagnostic and Interventional Radiology